Cough-Variant Asthma: Diagnostic Work-Up and Treatment
Initial Diagnostic Approach
In a patient with chronic dry cough without wheeze or dyspnea, perform baseline spirometry followed by methacholine inhalation challenge testing when spirometry is normal or non-diagnostic; a positive methacholine test confirms bronchial hyperresponsiveness consistent with cough-variant asthma, but definitive diagnosis requires documented resolution of cough with specific antiasthmatic therapy. 1
Key Clinical Features Supporting CVA Diagnosis
Chronic nonproductive cough as the sole manifestation is the hallmark of cough-variant asthma, distinguishing it from classic asthma which presents with wheezing, chest tightness, or dyspnea. 2, 3
Physical examination and spirometry are typically entirely normal at rest in CVA patients, making diagnosis challenging but not excluding asthma. 1, 2
Exercise-induced symptoms (difficulty breathing after exercise) strongly suggest bronchial hyperresponsiveness and support the diagnosis. 2
Diagnostic Testing Algorithm
Step 1: Baseline Spirometry
- Perform spirometry with bronchodilator response testing first; if reversible airflow obstruction is demonstrated (≥12% improvement in FEV₁), proceed directly to empiric asthma therapy. 1, 2
Step 2: Methacholine Challenge (when spirometry is normal)
Methacholine inhalation challenge testing is the primary diagnostic tool when history, physical examination, and spirometry are non-diagnostic. 1, 2
A negative methacholine test essentially excludes asthma due to its very high negative predictive power. 1, 2
Critical caveat: A positive methacholine test is consistent with but NOT diagnostic of CVA—it merely demonstrates bronchial hyperresponsiveness. 1, 2
Step 3: Assess Eosinophilic Inflammation (Optional but Helpful)
Measure fractional exhaled nitric oxide (FeNO) or obtain induced sputum eosinophil count (>3% is significant) to assess eosinophilic airway inflammation and predict corticosteroid responsiveness. 2, 4
This step helps differentiate CVA from non-asthmatic eosinophilic bronchitis (NAEB), which presents with eosinophilic inflammation but lacks airway hyperresponsiveness on methacholine testing. 2
Definitive Diagnosis
The diagnosis of CVA is established ONLY after documented resolution of cough with specific antiasthmatic therapy—not by methacholine testing alone. 1, 2
Treatment Algorithm
First-Line Therapy
Initiate inhaled bronchodilators (beta-agonists) and inhaled corticosteroids simultaneously as first-line therapy. 1, 2
Typical regimen: Inhaled corticosteroid (e.g., fluticasone 220 mcg or budesonide 360 mcg twice daily) plus short-acting beta-agonist as needed. 1
Expected timeline: Partial improvement often occurs after 1 week of inhaled bronchodilator therapy, but complete resolution of cough may require up to 8 weeks of treatment with inhaled corticosteroids. 1, 2
Important Treatment Pitfall
Inhaled corticosteroids themselves may induce or exacerbate cough due to aerosol constituents (particularly beclomethasone dipropionate dispersant); if this occurs, switch to a different inhaled corticosteroid formulation such as triamcinolone acetonide. 1
Second-Line Therapy (If Inadequate Response)
Add a leukotriene receptor antagonist (montelukast 10 mg daily), which appears particularly effective in treating cough due to asthma. 1, 2, 5
- Montelukast demonstrated a 75.7% mean reduction in cough frequency by 4 weeks in a randomized controlled trial of CVA patients. 5
Third-Line Therapy (Refractory Cases)
Consider a short course of oral corticosteroids (prednisone 30 mg daily for 2 weeks) for refractory cases after ruling out other causes. 2
Critical Differential Diagnoses to Exclude
Post-Viral/Post-Infectious Cough
Presents as persistent dry cough in a previously healthy person where all other URI symptoms resolved weeks earlier. 1
May have dyspnea, wheezing, reversible airflow obstruction, and positive methacholine test due to transient viral-induced bronchial hyperresponsiveness—this is NOT asthma. 1
Key distinction: Post-infectious cough is self-limited (3-8 weeks duration) and does not require long-term asthma therapy. 6
Non-Asthmatic Eosinophilic Bronchitis (NAEB)
Presents with chronic cough and eosinophilic inflammation (sputum eosinophils >3%) but lacks airway hyperresponsiveness on methacholine testing. 2, 4
Accounts for 13-33% of chronic cough cases. 2
Responds to inhaled corticosteroids but does not require bronchodilators. 4, 7
If methacholine testing cannot be performed and empiric steroid therapy is given, a response will not distinguish CVA from NAEB. 1
Clinical Course and Prognosis
Approximately 30% of CVA patients develop typical bronchial asthma (with wheezing and dyspnea) within several years, making CVA a potential precursor to classic asthma. 2, 4
In other patients, isolated cough remains the predominant or sole symptom indefinitely. 4
This progression risk underscores the importance of early recognition and treatment to reduce morbidity. 3
When to Reassess the Diagnosis
If cough persists beyond 8 weeks of appropriate asthma therapy, systematically re-evaluate for:
- Upper airway cough syndrome (UACS/post-nasal drip)
- Gastroesophageal reflux disease (GERD)
- Other causes of chronic cough
Chronic cough is frequently multifactorial; partial improvement with asthma treatment suggests continuing that therapy while adding treatment for other identified causes rather than stopping and switching. 6